Ligand id: 2031

Name: lanreotide

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Used to treat acromegaly, where other treatments have been unsucessful. May also be used to treat symptoms associated with neuroendocrine tumours such as TSH-secreting thyrotrophic adenomas.
Mechanism Of Action and Pharmacodynamic Effects
Endogenous somatostatin (via the somatostatin receptors) blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide mimics this effect. In acromegalic patients this drug reduces growth hormone and IGF-1 levels.
External links